ArticlebioRxiv : the preprint server for biology2026
Suppressing Primer-Driven Nonspecific Amplification in LAMP Using TrueLAMP.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loop-mediated isothermal amplification (LAMP) is widely used for rapid nucleic acid detection but is limited by primer-driven nonspecific amplification that produces false positives. We developed TrueLAMP, a colorimetric LAMP formulation containing an inhibitor that suppresses nonspecific amplification while preserving target-dependent reactions. Using SARS-CoV-2 as a model, TrueLAMP was evaluated across multiple primer sets. TrueLAMP eliminated amplification in no-template controls while maintaining robust target amplification, achieving 100% specificity across all no-template controls and, using the Lamb primer set as a representative benchmark, a limit of detection of 250 copies per reaction with 95% detection probability. Stable endpoint colorimetric signals were maintained over extended incubation periods, enabling flexible readout without time-critical monitoring. TrueLAMP is compatible with readily available equipment, including convection ovens and temperature-controlled smart mugs, supporting simplified and decentralized molecular testing workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.